Company Product Description Indication Status
Alpha Cognition Inc., of Vancouver, British Columbia Alpha-602 Progranulin Amyotrophic lateral sclerosis FDA granted orphan drug designation
Histogen Inc., of San Diego HST-001 Hair-stimulating complex Androgenic alopecia FDA approved its IND, and the company intends to initiate a phase Ib/IIa trial in the second quarter of 2020
Moderna Inc., of Cambridge, Mass. mRNA-1273 mRNA vaccine candidate COVID-19 FDA granted fast track designation
Seattle Genetics Inc., of Bothell, Wash. Tukysa (tucatinib) Oral, small-molecule tyrosine kinase inhibitor of HER2 Metastatic HER2-positive breast cancer Swissmedic granted approval for Tukysa tablets, in combination with trastuzumab and capecitabine, for the treatment of patients who have previously received 2 or more anti-HER2 regimens in any setting

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments